Influenza Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithK

Influenza Pipeline constitutes 120+ key companies continuously working towards developing 120+ Influenza treatment therapies, analyzes DelveInsight.

Influenza Overview:

Influenza is a highly contagious respiratory disease that causes seasonal epidemics and can range from mild symptoms to severe illness, including respiratory failure and death. It leads to significant health impacts, including work absenteeism, suffering, and mortality. According to the CDC, seasonal influenza caused between 24,000 and 62,000 deaths during the 2019-2020 season. The 2020-2021 season lacked sufficient data for burden estimates. Mortality rates are highest among infants and the elderly.

Influenza is traditionally diagnosed based on clinical symptoms, though rapid diagnostic tests with high specificity but moderate sensitivity are increasingly used. The gold standard is viral culture from nasopharyngeal or throat samples. For elderly or high-risk individuals with respiratory symptoms, chest X-rays may be performed to rule out pneumonia.

Prevention, through annual vaccination, is the most effective approach. The CDC updates the vaccine each year based on global trends. Historically, the vaccine was trivalent (protecting against three strains: A-H1, A-H3, and a B). In 2012, quadrivalent vaccines, which protect against an additional B strain, were introduced and became available starting the 2013-2014 flu season. For the 2021-2022 season, all flu vaccines were expected to be quadrivalent.

Request for a detailed insights report on Influenza pipeline insights @ https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Influenza Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Influenza Therapeutics Market.

Key Takeaways from the Influenza Pipeline Report

DelveInsight's Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment.
Key Influenza companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others are evaluating new drugs for Influenza to improve the treatment landscape.
Promising Influenza pipeline therapies in various stages of development include mRNA-1010, SAB-176, INNA-051, CODA-VAX H1N1, ALVR106, and others.

Influenza Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Influenza Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Influenza market.

Download our free sample page report on Influenza pipeline insights @ https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Influenza Emerging Drugs

mRNA-1010: Moderna
SAB-176: SAB Biotherapeutics
INNA-051: ENA Respiratory Pty Ltd
CODA-VAX H1N1: Codagenix
ALVR106: AlloVir

Influenza Companies

Over 120 major companies are working on developing therapies for influenza. Among them, Moderna has drug candidates for influenza in the most advanced stage, Phase III.

DelveInsight's report covers around 120+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Influenza Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Influenza Therapies and Key Companies: Influenza Clinical Trials and advancements @ https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Influenza Pipeline Therapeutic Assessment
• Influenza Assessment by Product Type
• Influenza By Stage
• Influenza Assessment by Route of Administration
• Influenza Assessment by Molecule Type

Download Influenza Sample report to know in detail about the Influenza treatment market @ Influenza Therapeutic Assessment @ https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Influenza Current Treatment Patterns
4. Influenza - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Influenza Late-Stage Products (Phase-III)
7. Influenza Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Influenza Discontinued Products
13. Influenza Product Profiles
14. Influenza Key Companies
15. Influenza Key Products
16. Dormant and Discontinued Products
17. Influenza Unmet Needs
18. Influenza Future Perspectives
19. Influenza Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Influenza Pipeline Reports Offerings: https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.